In recent years, ANGPTL3 has emerged as a promising target for ASCVD based on observations from preclinical and clinical studies demonstrating that inhibition of ANGPTL3 can lower proatherogenic lipids and in animal models reduce atherosclerosis. Here, ANGPTL3 is linked to atherosclerosis.